Retrospective Analysis of Immunotherapy Retreatment Following Immune-Related AEs in NSCLC Pts Treated With Anti–PD-(L)1 Therapy

Source: 2017 American Society of Clinical Oncology Annual Meeting*
Download Slideset
June 2-6, 2017; Chicago, Illinois
One half of patients with irAE-related dose interruptions experienced recurrent or new irAEs during immunotherapy retreatment.
Format: Microsoft PowerPoint (.ppt)
File Size: 760 KB
Released: June 5, 2017

Acknowledgements

Supported by educational grants by
AbbVie
Amgen
AstraZeneca
Celgene Corporation
Genentech
Halozyme Therapeutics
Incyte
Merck & Co., Inc.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings